Patients with CML in the lymphoid blastic phase have inferior response to anti-CD19 CAR T-cell therapy compared to de novo Ph-positive B cell acute lymphoblastic leukemia

Mei-Jing Liu; Kai-Wen Tan; Han-Yu Cao; Si-Man Huang; Chong-Sheng Qian; Sheng-Li Xue; Hai-Ping Dai; Wen-Jie Gong

doi:10.1002/hem3.49

Patients with CML in the lymphoid blastic phase have inferior response to anti-CD19 CAR T-cell therapy compared to de novo Ph-positive B cell acute lymphoblastic leukemia

Hemasphere. 2024 Feb 27;8(2):e49. doi: 10.1002/hem3.49. eCollection 2024 Feb.

Authors

Mei-Jing Liu^{1

2}, Kai-Wen Tan^{1

2}, Han-Yu Cao^{1

2}, Si-Man Huang^{1

2}, Chong-Sheng Qian^{1

2}, Sheng-Li Xue^{1

2}, Hai-Ping Dai^{1

2}, Wen-Jie Gong^{1

2}

Affiliations

¹ National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China.
² Institute of Blood and Marrow Transplantation Collaborative Innovation Center of Hematology, Soochow University Suzhou People's Republic of China.

No abstract available